Comparative Effectiveness of Ranolazine and Saroglitazar on Non Alcoholic Fatty Liver Disease in Patients with Diabetic Dyslipidemia A Randomised Controlled Open Label Trial

Comparative Effectiveness of Ranolazine and Saroglitazar on Non Alcoholic Fatty Liver Disease in Patients with Diabetic Dyslipidemia A Randomised Controlled Open Label Trial

dc.contributor.guide	Lakshmi, K S
dc.coverage.spatial
dc.creator.researcher	Ravula Sahithya Ravali
dc.date.accessioned	2022-08-04T09:54:12Z
dc.date.available	2022-08-04T09:54:12Z
dc.date.awarded
dc.date.completed	2022
dc.date.registered
dc.description.abstract	Non-alcoholic fatty liver disease (NAFLD) will be the principal reason for newlineongoing liver sickness of nations in west by 2030, and liver transplantation will become newlinemore widespread as a result. A common misconception about fatty liver is that it is the newlinehepatic aspect of metabolic syndrome because it is associated with insulin resistance (IR) newlineand dyslipidemia. Fatty liver is linked to Type 2 Diabetes Mellitus (T2DM) and is seen newlinein 70-80% of T2DM patients. Due to the lack of a standard treatment for NAFLD, current newlinetherapeutic techniques focus on treating diabetic dyslipidemia newline
dc.description.note
dc.format.accompanyingmaterial	DVD
dc.format.dimensions
dc.format.extent
dc.identifier.uri	http://hdl.handle.net/10603/397386
dc.language	English
dc.publisher.institution	Department of Pharmacy
dc.publisher.place	Kattankulathur
dc.publisher.university	SRM Institute of Science and Technology
dc.relation
dc.rights	university
dc.source.university	University
dc.subject.keyword	Clinical Medicine
dc.subject.keyword	Clinical Pre Clinical and Health
dc.subject.keyword	Critical Care Medicine
dc.title	Comparative Effectiveness of Ranolazine and Saroglitazar on Non Alcoholic Fatty Liver Disease in Patients with Diabetic Dyslipidemia A Randomised Controlled Open Label Trial
dc.title.alternative
dc.type.degree	Ph.D.